Market Overview

UPDATE: Sterne Agee Reiterates Underperform Rating, Raises PT on PAREXEL International Corporation

Related PRXL
Events for the Week of Sept. 2-5th
PAREXEL International Announces Acquisition Of ATLAS Medical Services, A Provider Of Clinical Research Services In Turkey

In a report published Monday, Sterne Agee Group reiterated its Underperform rating on PAREXEL International Corporation (NASDAQ: PRXL), and raised its price target from $23.50 to $27.00.

Sterne Agee noted, “As we discussed in a recent industry note (dated 1/7/13), we believe investors are under-pricing the risk inherent in PAREXEL. A much higher customer concentration and insufficient operational benefits accruing to clients from strategic partnerships (based on our industry checks) make PRXL a riskier investment than either CVD or CRL, in our opinion. Therefore, we use 15x CY14 to arrive at a $27 price target for PRXL; compares to 10-year average of 18x.”

PAREXEL International Corporation closed on Friday at $32.74.

Latest Ratings for PRXL

DateFirmActionFromTo
Aug 2014CitigroupMaintainsBuy
Aug 2014JefferiesMaintainsHold
Jul 2014KeyBancInitiates Coverage onHold

View More Analyst Ratings for PRXL
View the Latest Analyst Ratings

Posted-In: Sterne Agee GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (PRXL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters